Champions Oncology, Inc. (CSBR)
NASDAQ · Healthcare
Champions Oncology, Inc. EBITDA 2018–2025
Champions Oncology, Inc. annual/quarterly ebitda history and growth rate from 2018 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Champions Oncology, Inc. ebitda for the quarter ending January 31, 2026 was 65000, a 98.67% decrease year-over-year.
- Champions Oncology, Inc. ebitda for the twelve months ending January 31, 2026 was 5.3 M, a 910.79% decrease year-over-year.
- Champions Oncology, Inc. annual ebitda for 2025 was 6.2 M, a 212.77% decrease from 2024.
- Champions Oncology, Inc. annual ebitda for 2024 was -5.5 M, a 72.88% increase from 2023.
- Champions Oncology, Inc. annual ebitda for 2023 was -3.2 M, a 249.79% decrease from 2022.
- Champions Oncology, Inc. annual ebitda for 2022 was 2.1 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Champions Oncology, Inc. EBITDA — FAQ
Champions Oncology, Inc. (CSBR) ebitda over the last 8 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CSBR's ebitda history?
The chart and table above show Champions Oncology, Inc.'s ebitda by year and by quarter, including the growth rate.